JP Morgan: Contemporary Amperex Technology (03750) has competitive advantage in sodium-ion batteries, maintaining a "buy" rating.
In the field of energy storage batteries in China, Contemporary Amperex Technology (CATL) is the world's largest energy storage battery manufacturer and the first choice in the battery value chain in China.
JPMorgan released a research report stating that after communicating with experts in the US data center power solutions, they believe that the energy storage market for AI data centers (AIDC) will enter a rapid growth stage. The electricity demand of US data centers is expected to nearly double by 2030, and most new AIDCs will need battery storage systems to ensure reliability and optimization, with both utilization rate and storage duration increasing.
The bank believes that Contemporary Amperex Technology (03750) is the global leader in the commercialization of sodium-ion batteries, with the world's first platform-based sodium-ion energy storage solution and a 60GWh sodium-ion energy storage order with Hyperstrong. In the field of energy storage batteries in China, Contemporary Amperex Technology is the world's largest energy storage battery manufacturer and is the bank's preferred choice in the Chinese battery value chain. JP Morgan maintains a "hold" rating on Contemporary Amperex Technology's Hong Kong shares and (300750.SZ)A shares.
Related Articles
Hong Kong stock concept tracking | "May Day" diversified travel activates holiday economy, long-haul travel market outbreak, catering consumption, hotels and other areas attention (with concept stocks)

New stock news | Weijian Pharmaceutical's Hong Kong IPO prospectus fails to take effect.

New stock news | Haina Pharmaceuticals' Hong Kong stock IPO prospectus invalidated.
Hong Kong stock concept tracking | "May Day" diversified travel activates holiday economy, long-haul travel market outbreak, catering consumption, hotels and other areas attention (with concept stocks)
New stock news | Weijian Pharmaceutical's Hong Kong IPO prospectus fails to take effect.

New stock news | Haina Pharmaceuticals' Hong Kong stock IPO prospectus invalidated.






